{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-117406","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.924296+00:00","generated_at":"2026-05-30T09:58:57.290139+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MEI Pharma sells rights to ME-344 to Aardvark Therapeutics for up to $62.5M milestones","bullets":["Closed on Oct 22, 2024: sold ME-344 assets (IP, contracts, technology) to Aardvark Therapeutics for $0.5M upfront plus $55K reimbursement.","Potential milestone payments up to $62M tied to regulatory approval and sales milestones for ME-344.","Purchaser assumes certain liabilities under transferred contracts; no material relationship between parties.","Company retains all other assets and liabilities not specifically transferred (Excluded Assets and Liabilities)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-117406","json":"https://secwatch.observer/filing/0000950170-24-117406.json","markdown":"https://secwatch.observer/filing/0000950170-24-117406.md","text":"https://secwatch.observer/filing/0000950170-24-117406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024117406/0000950170-24-117406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024117406/meip-20241022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:58:57.290139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"142fcd08626ec59232a59c19f12d7f763607e60c","claim":"Lite Strategy, Inc. completed a disposition involving Aardvark Therapeutics, Inc. for $500,000 in cash plus the Reimbursement Amount and up to $62 million in Milestone Payments (closed 2024-10-22).","evidence_excerpt":"including relevant intellectual property rights, technology and contracts. Pursuant to the Asset Purchase Agreement, the Purchaser paid the Company an initial payment of $500,000 in cash plus the Reimbursement Amount (as defined in the Asset Purchase Agreement) at the closing of the transactions contemplated by the Asset Purchase Agreement (the “Closing”)","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024117406/0000950170-24-117406-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Aardvark Therapeutics, Inc."},{"label":"Consideration","value":"$500,000 in cash plus the Reimbursement Amount and up to $62 million in Milestone Payments"},{"label":"Closing","value":"2024-10-22"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}